Specifically, it was observed that Olaparib increased intratumoral CD4+ and CD8+ cells, decreased the production of inhibitory receptors, increased the recruitment and activity of tumor associated dendritic cells, therefore providing a robust immune activation both innate and adaptive. Here, CD4 is linked to neoplasm.